Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs

J Infect Dis. 2003 Feb 15;187(4):542-9. doi: 10.1086/374002. Epub 2003 Feb 7.


In two recent clinical trials, a vaccine containing herpes simplex virus (HSV) type 2 glycoprotein D (gD2) and a novel adjuvant AS04 comprising alum (Al) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegative women significant protection against HSV-2 genital disease (vaccine efficacy, 73% in study 1 and 74% in study 2) and limited protection against infection (46% in study 1 and 39% in study 2). In the present report, studies in the guinea pig model investigated the protection afforded by gD2/AS04 against HSV-1 and HSV-2 genital herpes and investigated whether immunization could prevent or reduce recurrent disease in guinea pigs that developed mucosal infection. Immunization with gD2/AS04 conveyed nearly complete protection against primary disease with either virus but did not prevent mucosal infection. Guinea pigs immunized with gD2/AS04 were significantly better protected against recurrent disease than were guinea pigs immunized with a gD2/Al vaccine, which suggests that inclusion of 3-dMPL improved protection against latent infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Female
  • Guinea Pigs
  • Herpes Genitalis / prevention & control*
  • Herpes Genitalis / virology
  • Herpes Simplex / prevention & control*
  • Herpes Simplex Virus Vaccines / administration & dosage*
  • Herpesvirus 1, Human*
  • Herpesvirus 2, Human* / immunology
  • Secondary Prevention
  • Vaccination*
  • Vaccines, Synthetic / administration & dosage
  • Viral Envelope Proteins / administration & dosage*
  • Viral Envelope Proteins / immunology


  • Herpes Simplex Virus Vaccines
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • glycoprotein D-herpes simplex virus type 2